Article Contents ::
- 1 Details About Generic Salt :: Spironol
- 2 Main Medicine Class:: Potassium-sparing diuretic
- 3 (SPEER-oh-no-LAK-tone) Aldactone, Spironolactone, Novo-Spiroton, Novo-Spirozine Class: Potassium-sparing diuretic
- 4 Drugs Class ::
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
Details About Generic Salt :: Spironol
Main Medicine Class:: Potassium-sparing diuretic
(SPEER-oh-no-LAK-tone)
Aldactone, Spironolactone, Novo-Spiroton, Novo-Spirozine
Class: Potassium-sparing diuretic
Drugs Class ::
Action Competitively inhibits aldosterone in distal tubules, resulting in increased excretion of sodium and water and decreased excretion of potassium.
Indications for Drugs ::
Indications Short-term preoperative treatment of primary hyperaldosteronism; long-term maintenance therapy for idiopathic hyperaldosteronism; management of edematous conditions in CHF, cirrhosis of liver and nephrotic syndrome; management of essential hypertension; treatment of hypokalemia. Unlabeled use(s): Treatment of hirsutism; relief of PMS symptoms; short-term treatment of familial male precocious puberty; and short-term treatment of acne vulgaris.
Drug Dose ::
Route/Dosage
Diagnosis of Primary Hyperaldosteronism
ADULTS: PO 400 mg/day for 4 days (short test) or 3 to 4 wk (long test).
Maintenance Therapy for Hyperaldosteronism
ADULTS: PO 100 to 400 mg daily in single or divided doses.
Edema
ADULTS: PO 25 to 200 mg/day in single or divided doses. CHILDREN: PO 3.3 mg/kg/day in single or divided doses.
Essential Hypertension
ADULTS: PO 50 to 100 mg/day in single or divided doses. CHILDREN: PO 1 to 2 mg/kg bid.
Diuretic-Induced Hypokalemia
ADULTS: PO 25 to 100 mg/day when oral potassium or other potassium-sparing regimens are inappropriate.
Contraindication ::
Contraindications Anuria; acute renal insufficiency; impaired renal excretory function; hyperkalemia.
Drug Precautions ::
Precautions
Pregnancy: Category D. Lactation: Excreted in breast milk. Electrolyte imbalances and BUN increase: Hyperkalemia (serum potassium > 5.5 mEq/L), hyponatremia, hypochloremia and increases in BUN may occur.
PATIENT CARE CONSIDERATIONS |
|
Drug Side Effects ::
Adverse Reactions
CNS: Drowsiness; lethargy; headache; mental confusion; ataxia. DERM: Maculopapular or erythematous cutaneous eruptions; urticaria. GI: Cramping; diarrhea; gastric bleeding; gastric ulceration; gastritis; vomiting. GU: Inability to achieve or maintain erection. HEMA: Agranulocytosis. META: Hyperchloremic metabolic acidosis in decompensated hepatic cirrhosis. OTHER: Gynecomastia; irregular menses or amenorrhea; postmenopausal bleeding; hirsutism; deepening of voice; drug fever; carcinoma of breast.
Drug Mode of Action ::
Action Competitively inhibits aldosterone in distal tubules, resulting in increased excretion of sodium and water and decreased excretion of potassium.
Drug Interactions ::
Interactions
ACE inhibitors: May result in severely elevated serum potassium levels. Digitalis glycosides: May decrease digoxin clearance, resulting in increased serum digoxin levels and toxicity; may attenuate inotropic action of digoxin. Mitotane: May decrease therapeutic response to mitotane. Potassium preparations: May severely increase serum potassium levels, possibly resulting in cardiac arrhythmias or cardiac arrest. Do not take with potassium preparations. Salicylates: May result in decreased diuretic effect.
Drug Assesment ::
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies.
- Assess fluid and electrolyte status prior to therapy.
- Monitor potassium levels. If level is > 5.5 mEq/L, withhold medication and notify physician.
- Monitor serum electrolytes, I&O, weight and BP daily.
- Monitor ABGs, liver and renal function studies.
- If deep rapid respirations or headaches develop, notify physician.
- Assess urinary status. If patient develops frequency, dysuria, edema or reduced urinary output, notify physician.
- Assess for any changes in hepatic status. If patient appears jaundiced and mentally confused, notify physician.
- If nausea, vomiting, distention, diarrhea or anorexia occur, notify physician.
- Note any changes in neurologic status. If drowsiness, ataxia, lethargy, confusion or headache occurs, notify physician.
|
Drug Storage/Management ::
Administration/Storage
- If single dose is prescribed, administer in morning.
- Take medication with food.
- May crush tablets and administer as suspension.
- Suspension is stable for 30 days under refrigeration. Protect from light.
- Store tablets at room temperature.
Drug Notes ::
Patient/Family Education
- Explain that medication’s full diuretic effect may not be achieved for 1 to 2 wk.
- Instruct patient to avoid large quantities of potassium-rich foods or potassium salt substitutes.
- For patient being treated for hypertension, explain that patient may feel tired for several wks because body needs to adjust to lowered BP.
- Instruct patient to take drug with food to minimize GI irritation.
- Tell patient to weigh self twice wkly and to notify physician of any increase.
- Instruct patient to notify physician if new symptoms develop.
- Tell patient to report these symptoms to physician: GI cramping, diarrhea, lethargy, thirst, headache, skin rash, menstrual abnormalities, deepening of voice and breast enlargement in men.
- Advise patient that drug may cause drowsiness and to use caution while driving or performing other tasks requiring mental alertness.
- Instruct patient not to take prescription or otc medications without consulting physician.